Advertisement

World Journal of Surgery

, Volume 42, Issue 8, pp 2642–2650 | Cite as

Impact of Hepatitis B Carrier Status on the Outcomes of Surgical Treatment of Colorectal Liver Metastases

  • Kin Pan Au
  • Kenneth Siu Ho Chok
  • Albert Chi Yan Chan
  • Wing Chiu Dai
  • Tan To Cheung
  • Chung Mau Lo
Original Scientific Report
  • 69 Downloads

Abstract

Background

Chronic hepatitis B virus (HBV) infection is associated with a lower incidence of colorectal liver metastases. We explored the impact of HBV carrier status on outcomes of surgical treatment of colorectal liver metastases.

Methods

A retrospective analysis was conducted for consecutive patients undergoing liver resection for colorectal liver metastases from 2000 to 2016. HBV carriers were matched with controls by propensity scoring.

Results

304 patients with known HBV carrier status who underwent resection of colorectal liver metastases were studied. From the 21 (6.9%) hepatitis B carriers, a more prolonged prothrombin time (12.1 vs. 11.3 s, OR 1.42, p = 0.027) was observed, and fewer major resections were performed (19.0 vs. 47.3%, OR 0.262, p = 0.018). After 1:5 propensity score matching, they were compared with 105 controls with similar liver function, tumour status and receiving similar treatments. Patients with chronic hepatitis B enjoyed better median disease-free survival (15.8 vs. 9.20 month, p = 0.032). Overall survivals (50.0 vs. 43.6 month, p = 0.15) were similar. Operating time (227 vs. 240 min, OR 1.00, p = 0.33), blood loss (0.50 vs. 0.37 L, OR 1.15, p = 0.62), hospital stay (6 vs. 6 day, OR 1.02, p = 0.48), operative morbidity (9.5 vs. 16.2%, OR 0.545, p = 0.44) and mortality (0 vs. 1.0%, OR 1.62, p = 0.77) were comparable. The use of antiviral agents did not affect survival of HBV carriers.

Conclusions

Chronic HBV infection confers oncological benefit to surgical treatment of colorectal liver metastases. Given satisfactory liver reserve, HBV carrier status did not affect operative morbidity or mortality.

Notes

Compliance with ethical standards

Conflicts of interest

The authors declared that they have no conflicts of interest.

References

  1. 1.
    Gomez D, Lobo DN (2011) Malignant liver tumours. Surgery 29:632–639Google Scholar
  2. 2.
    Geoghegan JG, Scheele J (1999) Treatment of colorectal liver metastases. Br J Surg 86:158–169CrossRefPubMedGoogle Scholar
  3. 3.
    Faivre J, Manfredi S, Bouvier AM (2003) Epidemiology of colorectal cancer liver metastases. Bull Acad Natl Med 187:815–822PubMedGoogle Scholar
  4. 4.
    Uetsuji S, Yamamura M, Yamaicchi K et al (1992) Absence of colorectal cancer metastasis to the cirrhotic liver. Am J Surg 164:176–177CrossRefPubMedGoogle Scholar
  5. 5.
    Cai B, Liao K, Song XQ et al (2014) Patients with chronically diseased livers have lower incidence of colorectal liver metastases: a meta-analysis. PLoS ONE 9:e108618CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Augustin G, Bruketa T, Korolija D et al (2013) Lower incidence of hepatic metastases of colorectal cancer in patients with chronic liver diseases: meta-analysis. Hepatogastroenterology 60:1164–1168PubMedGoogle Scholar
  7. 7.
    Song E, Chen J, Ou Q et al (2001) Rare occurrence of metastatic colorectal cancers in livers with replicative hepatitis B infection. Am J Surg 181:529–533CrossRefPubMedGoogle Scholar
  8. 8.
    Qiu HB, Zhang LY, Zeng ZL et al (2011) HBV infection decreases risk of liver metastasis in patients with colorectal cancer: a cohort study. World J Gastroenterol 17:804–808CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Adam R, Lucidi V, Bismuth H (2004) Hepatic colorectal metastases: methods of improving resectability. Surg Clin North Am 84:659–671CrossRefPubMedGoogle Scholar
  10. 10.
    Adam R, Pascal G, Castaing D et al (2004) Tumor progression while on chemotherapy A contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052–1064CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Choti MA, Sitzmann JV, Tiburi MF et al (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Abdalla EK, Vauthey JN, Ellis LM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sutherland F, Harris JC (2002) Claude Couinaud: a passion for the liver. Arch Surg 137:1305–1310PubMedGoogle Scholar
  14. 14.
    Lisa JR, Solomon C, Gordon EJ (1942) Secondary carcinoma in cirrhosis of the liver. Am J Pathol 18:137–140PubMedPubMedCentralGoogle Scholar
  15. 15.
    Doherty DG, Norris S, Maridgal-Estebas L et al (1999) The human liver contains multiple populations of NK cells, T cells, and CD3+ CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 163:2314–2321PubMedGoogle Scholar
  16. 16.
    Okuno K, Hirai N, Lee YS et al (1998) Involvement of liver-associated immunity in hepatic metastasis formation. J Surg Res 75:148–152CrossRefPubMedGoogle Scholar
  17. 17.
    Tordjmann T, Soulie A, Guettier C et al (1998) Perforin and granzyme B lytic protein expression during chronic viral and autoimmune hepatitis. Liver 18:391–397CrossRefPubMedGoogle Scholar
  18. 18.
    Song E, Chen J, Ouyan N et al (2001) Kupffer cells of cirrhotic rat livers sensitize colon cancer cells to Fas-mediated apoptosis. Br J Cancer 84:1265–1271CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Seitz G (2008) Warum sind Metastasen in zirrhotischen Lebern so selten? Ultraschall der Medizin 10:123–126CrossRefGoogle Scholar
  20. 20.
    Consolo M, Amoroso A, Spandidos DA et al (2009) Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). Int J Mol Med 24:143–152PubMedGoogle Scholar
  21. 21.
    İşlekel H, Oktay G, Terzi C et al (2007) Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Cell Biochem Funct 25:433–441CrossRefPubMedGoogle Scholar
  22. 22.
    Shalinsky DR, Brekken J, Zou H et al (1999) Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 878:236–270CrossRefPubMedGoogle Scholar
  23. 23.
    Abdalla EK, Adam R, Bilchik AJ et al (2006) Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13:1271–1280CrossRefPubMedGoogle Scholar
  24. 24.
    Fan ST, Lo CM, Poon RT et al (2011) Continuous improvement of survival outcomes of resection of hepatocellular carcinoma. Ann Surg 253:745–758CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2018

Authors and Affiliations

  • Kin Pan Au
    • 1
  • Kenneth Siu Ho Chok
    • 1
  • Albert Chi Yan Chan
    • 1
  • Wing Chiu Dai
    • 1
  • Tan To Cheung
    • 1
  • Chung Mau Lo
    • 1
  1. 1.Department of Surgery, Queen Mary HospitalThe University of Hong KongPokfulamHong Kong

Personalised recommendations